These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 29195617

  • 21. When should FDG-PET be used in the modern management of lymphoma?
    Barrington SF, Mikhaeel NG.
    Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
    [Abstract] [Full Text] [Related]

  • 22. Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review.
    Dubreuil J, Salles G, Bozzetto J, Tordo J, Djaïleb L, Berriolo-Riedinger A, Leenhardt J, Giammarile F, Meignan M, Skanjeti A.
    Nucl Med Commun; 2017 Jul; 38(7):563-576. PubMed ID: 28570287
    [Abstract] [Full Text] [Related]

  • 23. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ.
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [Abstract] [Full Text] [Related]

  • 24. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
    Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.
    J Clin Oncol; 2014 Sep 20; 32(27):3048-58. PubMed ID: 25113771
    [Abstract] [Full Text] [Related]

  • 25. [Diagnostic imaging of malignant lymphomas].
    Mokry T, Flechsig P, Dietrich S, Weber TF.
    Radiologe; 2020 May 20; 60(5):445-458. PubMed ID: 32240326
    [Abstract] [Full Text] [Related]

  • 26. PET/CT in Lymphoma: Current Overview and Future Directions.
    Cheson BD.
    Semin Nucl Med; 2018 Jan 20; 48(1):76-81. PubMed ID: 29195620
    [Abstract] [Full Text] [Related]

  • 27. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
    Li F, Zhu HY, Yu L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr 20; 19(2):523-7. PubMed ID: 21518522
    [Abstract] [Full Text] [Related]

  • 28. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K, Tatsumi M, Higuchi I, Inoue A, Nakajo K, Ishikawa J, Shimosegawa E, Kanakura Y, Nakamura H, Hatazawa J.
    Ann Nucl Med; 2008 Nov 20; 22(9):795-802. PubMed ID: 19039558
    [Abstract] [Full Text] [Related]

  • 29. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M, de Vos S, Czernin J.
    Radiol Clin North Am; 2008 Mar 20; 46(2):199-211, vii. PubMed ID: 18619376
    [Abstract] [Full Text] [Related]

  • 30. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
    Thanarajasingam G, Bennani-Baiti N, Thompson CA.
    Curr Treat Options Oncol; 2016 May 20; 17(5):24. PubMed ID: 27032646
    [Abstract] [Full Text] [Related]

  • 31. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann CA, Schirrmeister H, Reske SN.
    Cancer; 2001 Mar 01; 91(5):889-99. PubMed ID: 11251940
    [Abstract] [Full Text] [Related]

  • 32. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F.
    J Nucl Med; 2013 Aug 01; 54(8):1244-50. PubMed ID: 23674577
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C, Minoia C, Asabella AN, Nicoletti A, Altini C, Antonica F, Ficco M, Guarini A, Maggialetti N, Rubini G.
    Hell J Nucl Med; 2014 Aug 01; 17 Suppl 1():40-9. PubMed ID: 24392468
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
    Duell J, Buck AK, Hartrampf PE, Schlötelburg W, Schneid S, Weich A, Dreher N, Lapa C, Kircher M, Higuchi T, Samnick S, Serfling SE, Raderer M, Rasche L, Einsele H, Topp MS, Kosmala A, Werner RA.
    J Nucl Med; 2023 Dec 01; 64(12):1889-1894. PubMed ID: 37797975
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI.
    Grueneisen J, Sawicki LM, Schaarschmidt BM, Suntharalingam S, von der Ropp S, Wetter A, Ruhlmann V, Quick HH, Forsting M, Umutlu L.
    PLoS One; 2016 Dec 01; 11(6):e0157880. PubMed ID: 27327617
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.